Live from ash 2024 | ascentage pharma's bcl-2 inhibitor lisaftoclax in combinations demonstrates potential clinical benefit in patients with prior exposure to venetoclax

Rockville, md. and suzhou, china , dec. 10, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of lisaftoclax (apg-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), in a poster presentation at the 66th american society of hematology (ash) annual meeting, taking place in san diego, ca, the united states.
ASH Ratings Summary
ASH Quant Ranking